Table 1. Recipients features.
| Group | IRF n = 173 | DGF n = 178 | Dialysis n = 379 | p value |
|---|---|---|---|---|
| Gender (F/M), n | 71/102 | 66/112 | 139/240 | 0.602 |
| Age (y) ± SD | 50 ± 14 | 50 ± 13 | 53 ± 13 | 0.05 |
| Race (white/non-white/other), n | 110/58/05 | 129/48/01 | 257/114/08 | 0.297 |
| Cause of chronic renal disease | ||||
| Unknown CKD | 48 | 40 | 89 | |
| CGN | 33 | 39 | 84 | |
| Diabetic nephropathy | 37 | 39 | 108 | |
| Hypertensive nephrosclerosis | 29 | 23 | 42 | 0.105 |
| ADPKD/ALPORT | 13 | 15 | 25 | |
| T-I nephritis | 6 | 10 | 22 | |
| Urological congenital | 5 | 4 | 6 | |
| Others | 2 | 8 | 3 | |
| Type of dialysis | ||||
| HD | 148 | 156 | 362 | < 0.001 |
| PD | 24 | 19 | 11 | |
| No dialysis | 1 | 3 | 6 | |
| Time on dialysis (mo) median (25-75%) | 37 (22-62) |
32 (19-48) |
45 (27-74) |
< 0.001 |
| Transplant data | ||||
| Induction therapy | ||||
| ATG/Basiliximab | 64/107 | 52/125 | 131/246 | 0.492 |
| Baseline immunosuppression | ||||
| Tacrolimus | 170 | 177 | 374 | 0.932 |
| MPA | 168 | 176 | 375 |
CKD: chronic kidney disease; CGN: chronic glomerulonephritis; ADPKD: autosomal dominant polycystic kidney disease; T-I nephritis: tubulo-interstitial nephritis; ATG: anti-thymocyte globulin; MPA: mycophenolic acid; TAC: tacrolimus.